Malaria: a vaccine concept based on sickle haemoglobin's augmentation of an innate autoimmune process to band 3.
The protection from malaria afforded by sickle haemoglobin (and certain other haemoglobinopathies) suggests that it may be possible to utilise a common property that their erythrocytes share with both malaria-infected erythrocytes and senescent erythrocytes to develop a vaccine. All three conditions cause clustering of a specific protein molecule, band 3, on their erythrocyte's surface and this protein, when present on senescent erythrocytes at least, results in the immune recognition and removal of these by naturally occurring antibodies. It is hypothesised that if an up-regulated immune response to this protein on sickle cells is responsible for the benefit afforded to malaria patients then a vaccine using antigenic band 3 peptides may provide similar protection.
Kennedy
J R
JR
rkenned9@tampabay.rr.com
D000818:Animals; D001457:Anion Exchange Protein 1, Erythrocyte / Q000276:immunology*; D004912:Erythrocytes / Q000469:parasitology*; D006451:Hemoglobin, Sickle / Q000276:immunology*; D008288:Malaria / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D017780:Malaria Vaccines; D010963:Plasmodium falciparum / Q000235:genetics / Q000276:immunology*
D001457:Anion Exchange Protein 1, Erythrocyte; D006451:Hemoglobin, Sickle; D017780:Malaria Vaccines